Accepted for Publication: May 1, 2020.
Corresponding Author: Aaron M. Secrest, MD, PhD, Department of Dermatology, University of Utah, 30 N 1900 E, 4A330, Salt Lake City, UT 84132 (aaron.secrest@hsc.utah.edu).
Published Online: August 26, 2020. doi:10.1001/jamadermatol.2020.1852
Author Contributions: Drs Hopkins and Secrest had full access to all the study data and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Carlisle, Hopkins, Eliason, Secrest.
Acquisition, analysis, or interpretation of data: Carlisle, Flint, Duffin, Secrest.
Drafting of the manuscript: Carlisle, Flint, Hopkins, Secrest.
Critical revision of the manuscript for important intellectual content: Carlisle, Hopkins, Eliason, Duffin, Secrest.
Statistical analysis: Carlisle, Flint.Administrative, technical, or material support: Carlisle, Secrest.
Supervision: Secrest.
Conflict of Interest Disclosures: Dr Duffin reported grants and personal fees from Pfizer, personal fees from Amgen, grants and personal fees from AbbVie, personal fees from Janssen, grants and personal fees from Boehringer Ingerheim, grants and personal fees from Celgene, grants and personal fees from UCB, grants and personal fees from Eli Lilly, grants and personal fees from Novartis, grants from Regeneron, grants and personal fees from Sienna, and grants from Stiefel outside the submitted work. Dr Secrest receives support from a Dermatology Foundation Public Health Career Development Award as well as research grant support from the American Skin Association, National Eczema Association, and National Psoriasis Foundation. No other disclosures were reported.
4.Secrest
AM , Asgari
MM , Kourosh
AS , Barbieri
JS , Albrecht
J ; American Academy of Dermatology Drug Pricing and Transparency Task Force. Prior authorizations for dermatologic medications: an American Academy of Dermatology survey of US dermatology providers and staff.
J Am Acad Dermatol. 2017;77(4):784-786. doi:
10.1016/j.jaad.2017.05.008PubMedGoogle ScholarCrossref 6.US Government Accountability Office. Generic drugs under Medicare: Part D generic drug prices declined overall, but some had extraordinary price increases. August 12, 2016. Accessed July 16, 2020. https://www.gao.gov/products/GAO-16-706
12.Kostecki
J . Dermatology Practice Profile Survey: 2009 Report. American Academy of Dermatology Association; 2009.
17.Raper
JL , Willig
JH , Lin
H-Y ,
et al. Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic.
Clin Infect Dis. 2010;51(6):718-724. doi:
10.1086/655890PubMedGoogle ScholarCrossref